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1. Background 
The use of response adaptive randomization (RAR) is becoming more common in clinical trials (Journal 
of Clinical Oncology. 2011;29(6):606-609). Such designs will change the randomization ratio based on 
information on treatment effect that accumulates within the trial (this is done in the background and 
not by unblinding the investigators). This has the effect of increasing the number of patients who are 
assigned to the better performing treatment arm.  
Acute care research represents an area where this may be of particular benefit, since few effective 
treatments exist for many emergency conditions such as stroke. Within such high stakes diseases, it may 
be advantageous to have a trial designed to improve the overall outcomes (on the average) of the 
population enrolled by tilting randomization towards the better treatment (which could be the 
placebo/standard treatment or the experimental treatment) (JAMA. 2012;307(22):2377-2378). 
Previous work by this research team focused on the impact of surrogate consent on acute care research. 
(BMC Emergency Medicine 2013, 13:18) In the summer of 2011, 400 emergency department patients 
and their family members at the University of Michigan were interviewed and rated their willingness to 
participate in 5 treatment and research options in the event of a future, hypothetical stroke. Two of the 
scenarios described an acute stroke trial with or without response adaptive randomization. While not 
the primary focus of that research study, 58% of the subjects agreed to the trial with response adaptive 
randomization, and 21% agreed to the standard clinical trial with fixed randomization. From this 
previous work, we learned that it would be ideal to more comprehensively describe the research trial to 
hypothetical patients and simulate the process that is used in actual acute trial enrollments as much as 
possible.  
This informed our follow up study that occurred in the summer of 2012. We presented a hypothetical 
stroke scenario to 418 subjects presenting to the emergency department for other, non-critical 
complaints. Half the subjects were presented a hypothetical clinical trial with standard 1:1 
randomization, and half the subjects were presented a trial with RAR. There was significantly higher 
participation in the RAR trial (67.3%) versus the standard trial (54.5%), absolute increase: 12.8% (95% CI: 
3.7 to 22.2%). Interestingly, only 62% of the RAR group versus 85% of the standard randomization group 
were able to accurately identify the allocation procedure when queried at the end of the scenario. The 
overarching goal of this investigation is to adjust the brief trial description procedure to improve 
understanding of the trial allocation procedure for the RAR. Improving the communication of the trial 
procedures within a simulated situation that mimics the rapid discussion regarding an emergency 
research trial would be beneficial for future interventional research studies in acute stroke and other 
serious emergent conditions. 
2. Specific Aims 
1. To measure the impact of adding in brief questions for comprehension into the consent process of a 
simulated emergency stroke trial with the intent of maximizing understanding of the randomization 
procedure. 
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2. To determine if hypothetical trial participation is increased by the addition of the understanding 
questions to the consent process. 
3. To explore the thematics areas expressed in the questions that the research participants have 
regarding the hypothetical trial. 
3. Design 
Cross sectional survey of convenience sample of ED patients and their family members without stroke 
with random allocation to two hypothetical clinical trials.  
4. Inclusion/Exclusion Criteria 
Patients or family members must be age 18 or greater. They must agree to participate in study. Patients 
must be presenting to ED without stroke or alteration in mental status, with stable vital signs and also 
not located in a resuscitation bay. Patients in any isolation status (contact, droplet, etc) were not 
approached). 
5. Survey Procedures 
Patients will be screened in the emergency department based on chief complaint and vital signs from 
the emergency department information system Centricity or MiChart. If eligible, patients will be asked 
to participate after a brief description of the study by a co-investigator, consented, and interviewed in 
the emergency department.  In order to better simulate an at-risk stroke population, the oldest patients 
in the ED at any given time will be screened first. 
Verbal consent will be obtained from the patient to participate in the simulation and they will receive a 
handout regarding their research participation and its voluntary nature. Since this is minimal risk 
research, and the informed consent form would represent the collection of personal identifiers, formal 
written informed consent will not be obtained. 
If the patient’s eligible family member(s) also wish to participate they will be asked to leave the area 
while the scenario is being administered to the patient. 
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After consent is obtained, the patient will be randomized to one of  four groups: either receiving a 
scenario with the RAR trial or the standard clinical trial with or without the addition of comprehension 
questions. (The two groups without the addition of the comprehension questions will be exposed to the 
same procedure as the 418 patients from the 2012 study.) 
 
Group Trial Type Video Type Proportion N from 2012 N from 2014 
1 RAR Uninterrupted 25% 208 75 
2 Standard Uninterrupted 8.33% 210 25 
3 RAR Comprehension 50% 0 150 
4 Standard Comprehension 16.67% 0 50 
 
Four comprehension questions will be added to the videos for the two groups assigned to this 
intervention, all addressing research procedures relevant to the consent process and operation of the 
the trial. One of the questions specifically addresses the method of randomization and allocation. 
Details are found in appendix 2. The following items will be available to the subjects (depending on 
scenario): consent form for standard trial, consent form for RAR trial, and risk pictograph for stroke 
thombolysis (Stroke. 2010; 41(2): 300–306). 
The clinical scenario and all other aspects of the trial will be exactly the same. The patient will be told 
during this scenario that “time is of the essence” and that a decision needs to be made quickly, in an 
attempt to simulate the acute trial enrollment process for stroke. Randomization will occur in blocks of 4 
and 8, in order to maintain general numerical balance between the groups throughout the study. In 
addition, if the patient has a family member or other visitor present they will be asked to refrain from 
discussing the decision with the patient until after the scenario and data collection are completed.  
 
A detailed hypothetical trial protocol will be available to the investigators as a reference regarding 
questions that the research participant may ask; however the interviewer(s) will have reviewed the 
protocol extensively and have pilot tested the scenario and should be well equipped to answer nearly all 
potential questions regarding the hypothetical clinical trial. Notes will be taken regarding the patient’s 
questions regarding the research trial. In addition, the amount of time spent on questions will be 
captured as a continuous variable.  
A structured survey will be administered which asks whether the patient agrees to the hypothetical trial, 
along with demographics, stroke warning signs, along with a modified version of the ICQ-4 (which 
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excludes the fourth item which asks whether the study met expectations which would not be applicable 
for this hypothetical study – since they did not participate) instrument to assess adequacy of informed 
consent (Journal of Clinical Epidemiology. 2006;59(6):608-614). The participant will receive a handout on 
stroke warning signs at the end of the research procedures. 
At the end of this survey participation in the research will end and no follow up contact will be 
conducted. 
No protected health information or any other specific identifiers will be collected from the patients.  
The data collection / scenario instrument will be pilot tested in the spring and adjusted as necessary. 
Data collection for the project will proceed over the summer months. 
The research assistant (medical student) who is collecting the data will not have access to results within 
the database during the data collection phase. 
6. Analysis Plan 
Aim 1: The primary outcome will be difference in proportions for correct identification of the 
hypothetical trial allocation method between the comprehension questions (intervention) group versus 
the uninterrupted video group limited to the subjects assigned to the RAR groups. For the primary 
analysis, the 218 subjects from the 2012 study assigned to the RAR group will be included in the analysis. 
These 218 subjects will be fully weighted unless a chi-square test comparing the proportion correctly 
identifying the allocation methods from the 2012 study versus the “uninterrupted video”  group from 
the 2014 study indicates a significant difference between groups. In this case, for the primary analysis, 
each of the 2012 subjects will be weighted as 0.25 of an observation, thus placing approximately equal 
weight on the 2014 and 2012 subjects. Since these subjects are being exposed to exactly the same 
research procedure, we anticipate that there will not be heterogeneity and the subjects will be fully 
included in this analysis. As a pre-planned secondary analysis we will use multivariable logistic regression 
to estimate the adjusted odds of correctly identifying the allocation method within the RAR group, and 
include the following covariates based on our a priori belief about potential confounders: age, sex, 
ethnicity, and education. 
Aim 2: The pre-planned secondary outcome will be a difference in differences analysis. The outcome of 
interest here will be participation in hypothetical trial (same primary outcome as 2012). Proportions and 
95% confidence intervals for each of the four groups will be calculated with 2014 and 2012 groups 
(uninterrupted video) combined. The subjects from each of the 2012 groups included in this analysis will 
be fully weighted, unless a chi-square test indicates heterogeneity. (RAR uninterrupted 2014 versus RAR 
2012; Standard-uninterrupted 2014 versus standard 2012).  Logistic regression will be conducted with 
the following indicator variables as covariates: RAR trial versus standard, comprehension video versus 
uninterrupted, and interaction term. In addition, an adjusted model will be fitted including additional  
covariates were all included in the model based on our a priori belief about potential confounders: age, 
sex, ethnicity, education, self-reported understanding of protocol, ability to correctly identify allocation 
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technique and stroke awareness. 
Descriptive statistics for demographics and stroke knowledge will be calculated. 
 
Summary scores based in the ICQ-4 scale will also be calculated and comparisons will be made for trial 
accepters comparing the standard group and the RAR trial group. 
7. Sample Size 
We plan to enroll approximately 300 subjects. This should be feasible as 418 interviews were conducted 
during the previous summer and the current protocol is not significantly lengthened in terms of time.  
The correct identification proportion in the 2012 study was about 62%. If we have 150 new subjects in 
the comprehension questions group, and 75 new subjects in the uninterrupted video group (added to 
the 208 from 2012), we will have 90% power at the 0.05 significance level to detect an increase in the 
correct identification proportion to 77%, which would be clinically meaningful. (For reference, the 
standard randomization or “coin-flip” group correctly identified the randomization technique 85% of the 
time.) 
There is no pre-specified maximum number of subjects as this is a time-limited summer project. At the 
end of the 9th week (out of ten) enrollment of new subjects will terminate, unless the total sample size is 
not at least 300 subjects.  
The patients will be randomized in randomly permuted blocks (sizes 12 and 24) to ensure ongoing 
balance between the 4 groups. The randomization scheme was generated by using the Web site 
Randomization.com ⟨http://www.randomization.com⟨. The research assistant will only be able to 
access the assignment of the current patient, in order to properly administer the scenario.  
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Appendix 1: Recruitment Script 
Study Title: Consent in Hypothetical Acute 
Stroke Treatment 
Study Information 
We are conducting a research study to determine your preferences regarding acute 
stroke treatment and research. This study is completely voluntary and you can choose 
not to participate without any loss of potential benefits. 
There is no compensation for this study. You will receive a brief review of stroke 
warning signs as part of your participation. 
This study will take about 15 minutes of your time. You can choose not to answer any 
questions you are not comfortable answering. ---We will ask you to identify stroke 
warning signs. We will describe a situation in which you have a stroke, and then we will 
present a hypothetical research study. We will ask you whether you would participate in 
this research study. We will also allow you to ask questions about the hypothetical 
research study and then ask you some questions regarding the adequacy of the 
informed consent process for the hypothetical stroke study. 
We will then ask you several questions on demographics. At the end of the discussion, 
your participation will be completed. We will not collect any data which is personally 
identifiable to you. To ensure there is no chance that we inadvertently disclose 
documents that can identify you, we will NOT have you sign a consent form for this 
study (as this would create a document that has your identity). We will review stroke 
warning signs and provide you with an informational handout from the American Stroke 
Association. This study is funded by the University of Michigan Medical School.  
For questions about this study, please contact Dr. William J. Meurer, MD, MS: 
Alfred Taubman Health Care Center 
1500 East Medical Center Drive 
Room B1354 
Ann Arbor, MI 48109-5303 
Phone: 734-615-2766 
Email: wmeurer@umich.edu 
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Appendix 2: Script for video 
The added elements for the new comprehension questions are underlined below and 
only subjects randomized to these scenarios will be exposed to the comprehension 
questions. The RAR video can be viewed at http://youtu.be/cKIWduCaPZc; the standard 
trial video can be viewed at http://youtu.be/SrI4FdCTZ-A. 
Scenario 
After agreeing to participate, the participant will be randomized to being offered RAR 
versus standard trial.   
Overview 
Part 1: Introduction 
You have just suffered a stroke. Without warning, you are unable to move the right side 
of your body (arm or leg) and are unable to talk. You are also unable to understand 
what others are saying. You have been taken to the nearest emergency department and 
doctors have done tests and determined that this condition has been caused by a clot in 
one of the blood vessels in your brain. We will now describe several possible treatment 
options.  We want you to consider participating in this hypothetical trial, and ask 
questions that you would need answered if this was really occurring. We will provide an 
overview of the study and the alternative, standard treatment. We will also go over the 
hypothetical consent form for this study with you. You will then tell us whether you 
would want to participate in this study. Even though this scenario describes a situation 
in which you will not be able to talk, please answer the questions we will ask at the end 
regarding research participation and your understanding of the research protocol. 
IMPORTANT: If you have visitors with you, you may ask them to leave while we do this 
if you wish. However, it is important that you do not consult with your family members or 
friends during the scenario. Your family members and friends are also NOT allowed to 
ask questions regarding the protocol while we are collecting data. When the scenario is 
finished and we have completed data collection, we encourage you to talk with your 
family members or friends regarding these types of decisions, and we will attempt to 
answer any questions. We do recognize that in the event we are attempting to simulate, 
your family members would likely be very involved in the decision making process – 
however their task would be helping the researchers and physicians with choosing the 
treatment or research participation that YOU would want – which is why we are focusing 
on your opinions in this study.    
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You should have a copy of the consent form for this study with you for your reference. 
Part 2: Overview – Standard Treatment Drug tPA 
Following the stroke, you are a candidate for the standard treatment for a stroke, a drug 
called tissue plasminogen activator (tPA). This drug, tPA, has been FDA approved to 
reduce disability following stroke since 1996 and has been used extensively. It works by 
dissolving clots in the blood vessels of the brain. The original trial was funded by the 
U.S. government, and it is now recommended by the American Heart Association. 
When tPA is administered, for every 100 patients treated, about 13 extra patients would 
be left with no disability at 3 months when this drug is compared to receiving no acute 
treatment. By no disability we mean you would be able to walk on your own, care for 
yourself and return to work or other leisure activities that you enjoy. However, there is a 
small risk: about 6 out of every 100 patients treated with tPA will develop serious 
bleeding. Serious bleeding may include bleeding in the brain that could make symptoms 
worse or other bleeding that may require a transfusion. Still, there is no difference in the 
chance of dying whether you receive tPA or not. 
Comprehension question 1 is presented: 
Please choose the most appropriate option: 
tPA was previously demonstrated to do what? 
A. Reduce disability in selected stroke patients 
B. Save lives 
C. I don’t know 
The research subject is provided feedback on the correct answer after making a 
selection. (Answer A.) 
Part 3: Overview – Experimental Drug XPA 
The drug that is being investigated by this clinical research trial is an experimental drug, 
called XPA, or experimental plasminogen activator.  It has been used extensively for 
patients with heart attacks and is just now being investigated in patients with stroke. tPA 
(the standard treatment for stroke) was also previously used in heart attack patients 
prior to being approved for use in stroke.  This trial is being funded by the U.S. 
government, and it is designed to answer the question of whether XPA is potentially 
better and safer than the current standard treatment tPA. The reason we are doing the 
trial is because we are truly uncertain whether XPA is better than tPA. We have studied 
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this drug in other people with stroke in a smaller trial. It appeared as safe as tPA in 
stroke patients and was promising – we are doing this larger trial to determine if it is 
actually better. 
Comprehension question 2 is presented: 
Please choose the most appropriate option: 
Who is providing the money to do this research study on stroke? 
A. The drug company 
B. The U.S. government 
C. Medical insurance companies 
D. The hospital 
E. I don’t know 
The research subject is provided feedback on the correct answer after making a 
selection. (Answer: B) 
Part 4a: Standard Trial Script (skip to RAR trial Script if subject randomized to 
this) 
If you are watching this, the investigators in the hospital have reviewed your medical 
history and performed a complete neurological exam to ensure that you are a candidate 
for this study. 
If you choose NOT to enroll in the clinical research trial of XPA, you will instead have 
the following options: 1) Treatment with standard dose tPA given by IV; or 2) No 
immediate treatment for the stroke. You will still be admitted to the hospital and receive 
all other appropriate stroke therapies including physical therapy and speech therapy as 
necessary. 
If you choose to enroll in the clinical research trial of XPA, you will have a 50:50 chance 
of either receiving tPA (the standard treatment) or XPA (the new treatment). This will be 
determined by a computer and is similar to flipping a coin. This type of randomization is 
important to make sure that the groups receiving each of the medications are similar in 
every way, other than which treatment they receive. 
Comprehension question 3a is presented: 
Please choose the most appropriate option: 
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Who or what decides what treatment I get (xPA or tPA) in this trial? 
A. Randomization (something like a coin flip, with equal 50% chance of getting 
either for any individual in the trial including me) 
B. An algorithm informed by how well previous patients have done in this study, 
that still has some randomness (but might be like flipping a coin with an 80% 
chance of heads) 
C. The team of doctors and researchers caring for me will evaluate all available 
information and decide. 
D. I don’t know 
The research subject is provided feedback on the correct answer after making a 
selection (The correct response in this case is A.) 
In addition, in this trial, there will be a 3 month follow up to track how you are doing.  
You will be free to leave the study at any time, without penalty, but your reasons for 
leaving may be kept as part of the study record. The study will pay for research-related 
items and services.  However, you will not receive any compensation or benefits from 
participating, but we hope the information learned from this research study will help 
medical professionals understand how to help patients with stroke in the future. 
 
Part 4b: RAR Trial Script (don’t read if subject randomized to standard trial script) 
If you are watching this, the investigators in the hospital have reviewed your medical 
history and performed a complete neurological exam to ensure that you are a candidate 
for this study. 
If you choose NOT to enroll in the clinical research trial of XPA, you will instead have 
the following options: 1) Treatment with standard dose tPA given by IV; or 2) No 
immediate treatment for the stroke. You will still be admitted to the hospital and receive 
all other appropriate stroke therapies including physical therapy and speech therapy as 
necessary. 
If you choose to enroll in the clinical research trial of XPA, you will either receive tPA 
(the standard treatment) or XPA (the new treatment).  The chances of you receiving tPA 
or XPA will vary depending on which treatment has shown so far to be the best in 
reducing disability in patients similar to yourself so far in our study.  If no difference has 
been shown between the treatments so far in the study, you will have a 50:50 chance of 
receiving XPA versus tPA.  However, depending on how much better either treatment is 
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doing within those patients in whom we already have results, you may have as high as 
an 80:20 chance of receiving the better performing treatment.  At this point in time, 
across the U.S. approximately half of the total planned 700 patients have been enrolled. 
All of the researchers are blinded from the data of patients already enrolled, and the 
distribution of the better treatment is being determined by a computer that analyzes the 
ongoing results. 
Comprehension question 3b is presented: 
Please choose the most appropriate option: 
Who or what decides what treatment I get (xPA or tPA) in this trial? 
A. Randomization (something like a coin flip, with equal 50% chance of getting 
either for any individual in the trial including me) 
B. An algorithm informed by how well previous patients have done in this study, 
that still has some randomness (but might be like flipping a coin with an 80% 
chance of heads) 
C. The team of doctors and researchers caring for me will evaluate all available 
information and decide. 
D. I don’t know 
The research subject is provided feedback on the correct answer after making a 
selection (The correct response in this case is B.) 
In addition, in this trial, there will be a 3 month follow up to track how you are doing.  
You will be free to leave the study at any time, without penalty, but your reasons for 
leaving may be kept as part of the study record. The study will pay for research-related 
items and services.  However, you will not receive any compensation or benefits from 
participating, but we hope the information learned from this research study will help 
medical professionals understand how to help patients with stroke in the future. 
Part 5: Conclusions 
The XPA research study is funded by the National Institutes of Health and was 
designed by stroke researchers at the University of Saline. The companies whose 
products are being studied may benefit if the study demonstrates that this treatment 
combination is helpful. Saline Ann Arbor Pharmaceuticals are providing the study 
medications, but are not involved in the design of this research or the decision to 
publish results.  
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Comprehension question 4 is presented: 
Please choose the most appropriate option: 
What are the benefits of participating in this trial? 
A. The satisfaction of knowing that my participation is informing the care of future 
patients. 
B. Monetary compensation that will be paid directly to me by the researchers. 
C. I will definitely receive the superior treatment based on the described study 
procedures. 
D. I don’t know 
The research subject is provided feedback on the correct answer after making a 
selection (The correct response in this case is A.) 
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Appendix 3: Data Collection 
RAR-HypotheticalVersion1 
  
Q26 Enter Subject Number 
  
Q4 Please name as many stroke warning signs as you can. (Up to 5) 
-  Headache (1) 
-  Paralysis (2) 
- Trouble Speaking/Confusion (3) 
-  Change in Vision (4) 
-  Dizziness (5) 
-  None (6) 
  
Q19 Research Group: (filled out by research assistant) 
-  Standard CT (1) 
-  RAR  (2) 
  
 
Group Randomized to  
- Standard - Uninterrupted  
- RAR - Uninterrupted 
- Standard - Comprehension Questions 
- RAR - Comprehension Questions 
  
Q-TBA Click done when all the questions have been answered (timed question), notes will be taken on 
separate paper form and categorized. 
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Q2 Would you agree to participate in this clinical trial? (If unsure attempt to answer additional 
questions) 
-  Yes (1) 




Answer If Would you agree to participate in this clinical trial? (I... No Is Selected 
Q3 Would you wish to have the standard treatment rt-PA or no treatment at all? 
-  rt-PA (1) 




Q16 Did you understand the study when you decided to participate?  
-  Yes, completely (1) 
-  Mostly (2) 
-  Somewhat (3) 
-  Not at all (4) 
  
Q17 Did you understand the potential benefits as they were explained? 
-  Yes, completely (1) 
-  Mostly (2) 
-  Somewhat (3) 
-  Not at all (4) 
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Q18 Did you understand the potential risks as they were explained? 
-  Yes, completely (1) 
-  Mostly (2) 
-  Somewhat (3) 
-  Not at all (4) 
  
Q27 If you were in the hypothetical trial, how would the experimental treatment XPA versus the 
standard treatment tPA be picked?  
-  The study would use randomization, something like flipping a coin (1) 
-  The study would use an algorithm that would give me a higher chance of receiving whichever 
treatment was looking better in the trial so far. (2) 
-  My doctors would decide (3) 
-  Don't know / do not remember (4) 
  
Q5 What is your age?  
  
Q6 What is your gender? 
-  Male (1) 
-  Female (2) 
-  Prefer not to answer (3) 
  




Q8 Have you had a stroke before? 
-  Yes (1) 
-  No (2) 
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-  Prefer not to answer (3) 
  
Q9 Do you have high blood pressure? 
-  Yes (1) 
-  No (2) 
-  Prefer not to answer (3) 
  
Q10 Do you have diabetes? 
-  Yes (1) 
-  No (2) 
-  Prefer not to answer (3) 
  
Q11 Do you have atrial fibrillation? 
-  Yes (1) 
-  No (2) 
-  Prefer not to answer (3) 
  
Q12 Have you had a heart attack before? 
-  Yes (1) 
-  No (2) 




Q13 What is the highest level of education you have achieved?  
-  Some high school (1) 
-  High school graduate (2) 
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-  Some college (3) 
-  College graduate (4) 
-  Post-graduate degree (Master's, PhD, MD, JD, MSW, etc) (5) 
-  Prefer not to answer (6) 
  
Q14 We are interested in knowing about the composition of the community that you live in and will use 
census data to collect that information.  In order for us to determine this, could you tell us your zip 
code? (If prefer not to answer, leave blank) 
  
Q15 What is your race / ethnicity?  
-  White, Non-Hispanic (1) 
-  African American (2) 
-  Hispanic (3) 
-  Asian (4) 
-  Pacific Islander (5) 
-  Native American (6) 
-  Other (7) ____________________ 
-  Prefer not to answer (8) 
 
 
 
